Clinical Trial Update: Study of Multiple Oral Doses of Odanacatib (MK0822) in Healthy Adults (0822-002) [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating multiple oral doses of odanacatib (MK0822) in healthy adults has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis

Drugs mentioned

• Odanacatib (MK0822) (odanacatib)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Osteoporosis | Phase 1 | Status: COMPLETED